Fig. 2From: Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancerTumor markers of a patient with pancreatic cancer (a) and a patient with metastasized C-cell carcinoma (b) before, during and after treatment with 700 mg (a) and 2000 mg (b) Helixor® P. After 3 weeks in the study, treatment was continued off label until tumor markers increased againBack to article page